SELECTIVE ELIMINATION OF EROSIVE CELLS

The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.

Saved in:
Bibliographic Details
Main Authors GALSGAARD, ELISABETH DOUGLAS, SOEDERSTROEM, KALLE
Format Patent
LanguageEnglish
Published 28.12.2023
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The current invention relates to the treatment of diseases characterized by cartilage destruction and/or bone erosion. In particular the present invention relates to the treatment of osteoarthritis, osteoporosis, psoriatic arthritis or rheumatic arthritis with an anti-NKG2A antibody.
Bibliography:Application Number: US202318321810